PMID- 37632966
OWN - NLM
STAT- MEDLINE
DCOM- 20231204
LR  - 20231216
IS  - 1078-6791 (Print)
IS  - 1078-6791 (Linking)
VI  - 29
IP  - 8
DP  - 2023 Nov
TI  - Enhancing Diagnostic Accuracy for Lung Cancer through Combined Detection of 
      Multiple Tumor Markers.
PG  - 36-41
LID - AT8320 [pii]
AB  - OBJECTIVE: To explore the application value of combined detection of multiple 
      tumor markers in diagnosing lung cancer (LC). METHODS: A total of 32 small cell 
      lung cancer (SCLC) patients and 107 non-small cell lung cancer (NSCLC) patients, 
      including 68 lung adenocarcinoma (LADC) patients and 39 lung squamous cell 
      carcinoma (LSCC) patients diagnosed in our hospital from January 2019 to December 
      2021, were enrolled. 102 benign lung disease (BCD) patients (including pneumonia, 
      pulmonary tuberculosis, and chronic obstructive pulmonary disease) were chosen as 
      the control group. Serum tumor markers were detected in all patients, and their 
      positive rates and concentrations were compared. Receiver operating 
      characteristic (ROC) curve analysis was used to calculate the diagnostic 
      performance of individual and combined tests. RESULTS: The positive rate and 
      concentration of carcinoembryonic antigen (CEA) were upregulated in the LADC 
      group (P < .05). The positive rate and concentration of squamous cell carcinoma 
      antigen (SCCAg) were upregulated in the LSCC group (P < .05). The positive rate 
      and concentration of carbohydrate antigen 153 (CA153) were upregulated in the 
      SCLC group (P < .05). The positive rate and concentration of cytokeratin fragment 
      antigen 21-1 (CYFRA21-1) were the highest in the LADC and LSCC groups. The ROC 
      curve demonstrated that CEA exhibited higher diagnostic sensitivity and 
      specificity in LADC patients, SCCAg exhibited higher diagnostic sensitivity and 
      specificity in LSCC patients, and CYFRA21-1 exhibited the highest diagnostic 
      sensitivity in LADC and LSCC patients. In combined detection, the 4-marker 
      combined detection and single-marker combined detection showed statistical 
      significance in patients with different pathological types of LC (P < 0.05). 
      CONCLUSIONS: CYFRA21-1 combined with CEA assists in diagnosing LADC, CYFRA21-1 
      combined with SCCAg assists in diagnosing LSCC, and CA153 assists in diagnosing 
      SCLC. These four serum tumor markers can be used to aid in diagnosing LC and 
      differentiating its pathological types.
FAU - Qing, Gang
AU  - Qing G
FAU - Jiang, Xian
AU  - Jiang X
FAU - Xu, Guohua
AU  - Xu G
FAU - Liu, Ting
AU  - Liu T
FAU - Deng, Taibing
AU  - Deng T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Altern Ther Health Med
JT  - Alternative therapies in health and medicine
JID - 9502013
RN  - 0 (antigen CYFRA21.1)
RN  - 0 (Carcinoembryonic Antigen)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Humans
MH  - *Lung Neoplasms/diagnosis
MH  - Carcinoembryonic Antigen
MH  - Biomarkers, Tumor
MH  - *Carcinoma, Non-Small-Cell Lung/diagnosis
MH  - *Carcinoma, Squamous Cell/diagnosis
EDAT- 2023/08/27 05:43
MHDA- 2023/12/04 12:42
CRDT- 2023/08/26 17:53
PHST- 2023/12/04 12:42 [medline]
PHST- 2023/08/27 05:43 [pubmed]
PHST- 2023/08/26 17:53 [entrez]
AID - AT8320 [pii]
PST - ppublish
SO  - Altern Ther Health Med. 2023 Nov;29(8):36-41.